General Biotechnologies
General Bio grows GLP-1 and other peptides inside edible microbes, delivered as low-cost oral powders.
The problem
One in eight US adults now takes a GLP-1. The first oral versions reached the market this year, but they hit the same wall: absorption. So little of an oral peptide survives the gut that a pill needs close to 50 times more active compound than the injection. At up to $100,000 a kilogram to synthesise, that turns a 20-cent dose into a roughly $150 monthly supply. The barrier to a cheap, effective oral GLP-1 is cost.
The solution
General Bio uses DNA engineering to express therapeutic peptides directly inside a volcanic microbe discovered in George Church's lab in 2023, a distant relative of edible spirulina that doubles every two hours. Its thick cell wall acts as a natural enteric capsule, shielding the peptide from stomach acid and releasing it further down the tract. The GLP-1 can then be swallowed as a stable powder at room temperature, with no injection and no specialty pharmacy. Because the peptide stays locked inside an edible cell, General Bio skips downstream purification, the step that can account for up to 80% of peptide manufacturing cost. That is how the company reaches its $3 to $5 per patient per day target. Three products are now in development for a 2027 launch, at a new cGMP facility in Fremont, California, built with Persist AI and Valentia Analytical. The company is already lining up North American distribution partners.
